CY1111213T1 - Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας - Google Patents

Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας

Info

Publication number
CY1111213T1
CY1111213T1 CY20111100212T CY111100212T CY1111213T1 CY 1111213 T1 CY1111213 T1 CY 1111213T1 CY 20111100212 T CY20111100212 T CY 20111100212T CY 111100212 T CY111100212 T CY 111100212T CY 1111213 T1 CY1111213 T1 CY 1111213T1
Authority
CY
Cyprus
Prior art keywords
igf
binding protein
patient
risk
preterm birth
Prior art date
Application number
CY20111100212T
Other languages
Greek (el)
English (en)
Inventor
Lois Smith
Ann Hellström
Original Assignee
Premacure Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0004405A external-priority patent/SE0004405D0/xx
Application filed by Premacure Ab filed Critical Premacure Ab
Publication of CY1111213T1 publication Critical patent/CY1111213T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
CY20111100212T 2000-11-28 2011-02-22 Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας CY1111213T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0004405A SE0004405D0 (sv) 2000-11-28 2000-11-28 New composition and use
US27425201P 2001-03-09 2001-03-09
EP01987331A EP1402266B1 (en) 2000-11-28 2001-11-13 Reducing RISK OF COMPLICATIONS OF PREMATURITY

Publications (1)

Publication Number Publication Date
CY1111213T1 true CY1111213T1 (el) 2015-06-11

Family

ID=26655321

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100212T CY1111213T1 (el) 2000-11-28 2011-02-22 Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας

Country Status (9)

Country Link
US (2) US7144707B2 (cg-RX-API-DMAC10.html)
EP (1) EP1402266B1 (cg-RX-API-DMAC10.html)
JP (2) JP4173732B2 (cg-RX-API-DMAC10.html)
AT (1) ATE495443T1 (cg-RX-API-DMAC10.html)
AU (2) AU2002239560B2 (cg-RX-API-DMAC10.html)
CA (1) CA2429615C (cg-RX-API-DMAC10.html)
CY (1) CY1111213T1 (cg-RX-API-DMAC10.html)
DE (1) DE60143858D1 (cg-RX-API-DMAC10.html)
WO (1) WO2002043578A2 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1561228A (zh) * 2001-07-27 2005-01-05 哈特穆特M·汉瑙斯克－阿贝尔 增强新生儿的器官成熟度并预测重症监护时间
CN101553254A (zh) * 2006-10-03 2009-10-07 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
WO2008130315A1 (en) 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
RU2338193C1 (ru) * 2007-07-18 2008-11-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ прогнозирования развития ретинопатии недоношенных
MX2010002562A (es) 2007-09-07 2011-04-11 Inst Nac De Ciencias Medicas Y Nutricion Uso de los niveles de antigeno secretor, de lewis y de sialilo como predictores para enfermedad.
AU2008325142A1 (en) * 2007-11-07 2009-05-14 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
JP5398054B2 (ja) * 2008-08-20 2014-01-29 株式会社 資生堂 「シミ」の蓋然性の評価方法
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
RU2445945C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445946C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445944C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445943C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
RU2526827C1 (ru) * 2013-05-23 2014-08-27 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ прогнозирования развития пороговой стадии ретинопатии недоношенных у детей без офтальмологических признаков заболевания
JP5559406B2 (ja) * 2013-09-11 2014-07-23 株式会社 資生堂 シミを有する蓋然性を評価する方法
RU2536284C1 (ru) * 2013-09-19 2014-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Министерства здравоохранения Российской Федерации" (ГБОУ ВПО РНИМУ Минздрава России) Способ оценки тяжести течения и возможного исхода ретинопатии у недоношенных детей
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
RU2724013C2 (ru) * 2015-06-19 2020-06-18 Сера Прогностикс, Инк. Пары биологических маркеров для предсказания преждевременных родов
RU2639134C2 (ru) * 2016-01-21 2017-12-19 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ прогнозирования развития внутрижелудочковых кровоизлияний у новорожденных, родившихся после экстракорпорального оплодотворения
EP3681602B1 (en) * 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
RU2741727C1 (ru) * 2020-07-06 2021-01-28 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ прогнозирования развития внутрижелудочковых кровоизлияний у недоношенных новорожденных
RU2741722C1 (ru) * 2020-07-06 2021-01-28 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ прогнозирования внутрижелудочковых кровоизлияний у недоношенных новорожденных
EP3936054A1 (en) * 2020-07-08 2022-01-12 Assistance Publique - Hôpitaux de Paris Method of prognosis of bronchopulmonary dysplasia in premature infants
CN113528688A (zh) * 2021-09-09 2021-10-22 北京泱深生物信息技术有限公司 微生物在制备用于诊断生长发育迟缓的产品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2033176C (en) * 1989-06-09 1999-12-14 Julian Richard Este Wells Growth hormone fusion proteins
SE9002731D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product comprising growth factor
EP0956041A1 (en) * 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CN1561228A (zh) 2001-07-27 2005-01-05 哈特穆特M·汉瑙斯克－阿贝尔 增强新生儿的器官成熟度并预测重症监护时间

Also Published As

Publication number Publication date
ATE495443T1 (de) 2011-01-15
EP1402266A4 (en) 2007-12-12
AU3956002A (en) 2002-06-11
US20070196857A1 (en) 2007-08-23
JP2008163043A (ja) 2008-07-17
US7144707B2 (en) 2006-12-05
JP5089443B2 (ja) 2012-12-05
CA2429615C (en) 2016-07-12
JP2004528529A (ja) 2004-09-16
WO2002043578A3 (en) 2003-12-31
US20040053838A1 (en) 2004-03-18
EP1402266A2 (en) 2004-03-31
AU2002239560B2 (en) 2006-03-02
JP4173732B2 (ja) 2008-10-29
US7776820B2 (en) 2010-08-17
DE60143858D1 (de) 2011-02-24
EP1402266B1 (en) 2011-01-12
WO2002043578A2 (en) 2002-06-06
CA2429615A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
AU3956002A (en) Determination of risk and treatment of complications of prematurity
Bacq et al. Liver function tests in normal pregnancy: a prospective study of 103 pregnant women and 103 matched controls
Zidar et al. Unfavorable course of minimal change nephrotic syndrome in children with intrauterine growth retardation
Geethanath et al. Effect of timing of cord clamping on the iron status of infants at 3 months
Austin et al. Pregnancy-specific protein B induces release of an alpha chemokine in bovine endometrium
Polak et al. Fetal thyroidology
Erdem et al. The effect of maternal anemia and iron deficiency on fetal erythropoiesis: comparison between serum erythropoietin, hemoglobin and ferritin levels in mothers and newborns
JP2004528529A5 (cg-RX-API-DMAC10.html)
WO2014066568A1 (en) Non-invasive biomarker to identify subjects at risk of preterm delivery
Boroditsky et al. Serum human chorionic gonadotropin and progesterone patterns in the last trimester of pregnancy: relationship to fetal sex
Lindqvist et al. Epidermal growth factor in maternal urine—a predictor of intrauterine growth restriction?
Khadem et al. Comparison of serum levels of Tri‐iodothyronine (T3), Thyroxine (T4), and Thyroid‐Stimulating Hormone (TSH) in preeclampsia and normal pregnancy
Zimanyi et al. Nephron number and blood pressure in rat offspring with maternal high-protein diet
Tjoa et al. Plasma hepatocyte growth factor as a marker for small-for-gestational age fetuses
Setia et al. Increased insulin sensitivity in intrauterine growth retarded newborns–do thyroid hormones play a role?
Weems et al. PGE2 induces its own secretion in vitro by bovine 270-day placenta but not by 200-day placenta
Akram et al. Placental IGF‐I, IGFBP‐1, zinc, and iron, and maternal and infant anthropometry at birth
Hsu et al. Maternal serum screening for Down syndrome in pregnancies conceived by intra‐uterine insemination
Senses et al. Is there a relationship between cord blood pregnancy-associated plasma protein-A and birth weight and length?
Pellicer et al. Prenatal brain damage in preeclamptic animal model induced by gestational nitric oxide synthase inhibition
Satyanarayan et al. Maternal thyroid profile in pre-eclampsia
Kanawala et al. Prevalence of hypothyroid dysfunction among third trimester pregnant women and its effect on maternal and fetal outcome
Weems et al. Effects of prostaglandin F2α (PGF2α) on secretion of pregnancy specific protein B (PSPB) and placentome weights in intact or ovariectomized 90 to 100 day pregnant ewes
Panigrahi et al. Prevalence of Antiphospholipid Antibodies in Patients with Bad Obstetric History of unknown Etiology and Its Association with Clinical Parameters
Kajita et al. Clinical study on increased serum thyroxine-binding globulin in cancerous state